Recent Articles in IPO/Stock Watch

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the pricing range. MicroTech is the only China company with an approved patch insulin pump, which was launched in 2018. The company also offers a traditional blood glucose monitoring device and is developing a continuous blood glucose monitoring device. It has an additional six diabetes products in early development. MicroTech would have a market capitalization of $1.3 billion at the top of the range. More details....

Stock Symbol: (HK: 2235)

Share this with colleagues:

LianBio, a Princeton, NJ-Shanghai biopharma, has filed for a $100 million IPO on the NASDAQ exchange. LianBio currently has a pipeline of nine in-licensed candidates in five therapeutic areas including oncology. The company was formed by US-based Perceptive Investors to bring promising products from its large portfolio of life science companies to China's market, while LianBio also in-licenses candidates from other companies. More details....

Share this with colleagues:

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Its products, which are marketed in China and globally, address navigation, diagnosis and treatment needs for lung cancer, COPD and emphysema. The IPO was priced at the top end of the range, but on its first day of trading, Broncus' shares dropped 20%. Founded in 2012, Broncus posted net losses of $32.6 million in 2019 and $48.8 million in 2020, with revenue falling 59% in 2020. More details....

Stock Symbol: (HK: 2216)

Share this with colleagues:

Sino Biological, a Beijing company that offers biological research reagents and related contract research services to global markets, completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock closed 68% higher at a market capitalization of $5.2 billion. The company, which was founded in 2007, said the IPO funds would represent a new starting point, allowing Sino Biological to expand its existing capabilities. More details....

Stock Symbol: (SHZ: 301047)

Share this with colleagues: